Geovax announces 1-for-15 reverse stock split to regain compliance with nasdaq minimum bid requirement

Atlanta, ga, jan. 29, 2024 (globe newswire) -- via newmediawire – geovax labs, inc.  (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the company's board of directors has approved a reverse stock split of its issued and outstanding shares of common stock, par value $0.001 per share (the "common stock"), at a ratio of 1-for-15. the company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued listing on the nasdaq capital market under nasdaq listing rule 5550(a)(2). the reverse stock split was approved by the company's stockholders at a meeting held january 16, 2024.
GOVX Ratings Summary
GOVX Quant Ranking